IRF2 Knockout A-549 Polyclonal Cells consist of a polyclonal population of the A-549 human lung adenocarcinoma cell line bearing CRISPR/Cas9-mediated gene disruption of IRF2. As a polyclonal knockout pool, this product provides a heterogeneous loss-of-function system for investigating interferon regulatory factor 2 function without requiring clonal isolation. The cells are provided as a cryopreserved stock and are suitable for immediate culture and a variety of functional assays in an epithelial cancer background.
The A-549 parental line is a well-characterized model derived from a 58-year-old Caucasian male with lung carcinoma. These adherent cells exhibit characteristics of type II alveolar epithelial cells, including expression of surfactant proteins, and harbor an oncogenic KRAS mutation. They are extensively applied in lung adenocarcinoma, viral infection, and airway biology research, making them a physiologically relevant host for studying IRF2 knockout effects.
IRF2 functions as a transcriptional repressor that competitively inhibits IRF1 by binding interferon-stimulated response elements (ISREs). It lies downstream of type I (IFN-??/??) and type II (IFN-??) interferons, with expression induced by the ISGF3 complex (STAT1/STAT2/IRF9) after activation of receptor-associated kinases JAK1 and TYK2. IRF2 homodimers directly repress interferon-stimulated genes such as IFNB, ISG15, OAS1, and MX1, and also regulate CIITA and TP53. IRF2 interacts with multiple partners including IRF1, STAT1, NF-??B p65, PCAF, BRCA1, and IRF8, thereby integrating JAK-STAT, NF-??B, and p53 signaling. In knockout A-549 cells, loss of IRF2 relieves ISRE-mediated repression, leading to enhanced ISG expression and altered cellular response dynamics.
Within the KRAS-mutant A-549 adenocarcinoma environment, IRF2 knockout offers a powerful system to probe tumor-intrinsic immune signaling, cell cycle control, and apoptosis. Loss of IRF2-mediated repression is predicted to upregulate MHC class I and antigen presentation components like CIITA, potentially increasing tumor immunogenicity. The polyclonal pool recapitulates the natural variation in gene editing outcomes, providing a more representative model than clonal lines for examining heterogeneous responses in cancer cell populations and dissecting JAK-STAT/NF-??B pathway crosstalk.
Researchers can use this polyclonal knockout product to study interferon regulation, lung cancer biology, and to screen immune modulators. Experimental approaches include immunoblotting for IRF2 and ISG proteins, RT-qPCR quantification of ISG mRNAs, ChIP-qPCR analysis of IRF2-DNA binding, dual-luciferase reporter assays for ISRE activity, flow cytometric measurement of MHC-I surface levels, cell proliferation assays (MTT/CCK-8), Annexin V apoptosis detection, and transcriptome-wide RNA-seq. For product inquiries, please contact Ascent Research.
